A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

192

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG

S-337395

S-337395 will be administered per schedule specified in the arm description.

DRUG

Placebo

Placebo matched to S-337395 will be administered per schedule specified in the arm description.